Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 4Irinotecan 3abemaciclib 2Radiotherapy 2Cyclophosphamide 2Bevacizumab 2palbociclib 1dostarlimab 1dinutuximab 1adavosertib 1Vorinostat 1Vincristine 1Valproic Acid 1Topotecan 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiation 1Mebendazole 1Granulocyte-Macrophage Colony-Stimulating Factor 1Etoposide 1Eflornithine 1Carboplatin 1CLR1404 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × Eflornithine × Sarcoma × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡